What are the detailed evidence‑based recommendations and supporting studies for respiratory support, surfactant administration, and ventilation strategies in an infant born at less than 28 weeks gestation weighing under 1000 g?

Detailed Evidence-Based Respiratory Management for Infants <28 Weeks Gestation and <1000g

For extremely preterm infants <28 weeks gestation, initiate CPAP immediately at birth (5-6 cm H₂O), followed by selective surfactant administration via less invasive surfactant administration (LISA) technique when FiO₂ requirements exceed 0.30-0.40, rather than routine prophylactic intubation and surfactant. This approach reduces bronchopulmonary dysplasia (BPD) and death compared to prophylactic surfactant strategies in the modern era of antenatal steroids and early CPAP stabilization 1, 2, 3.

Initial Stabilization and Respiratory Support at Birth

Immediate Delivery Room Management

• Start with CPAP at 5-6 cm H₂O immediately after birth rather than routine intubation 2
• Target oxygen saturation goals appropriate for gestational age (typically 85-95% by 10 minutes)
• Avoid sustained inflations >5 seconds duration—this is potentially harmful and increases mortality in infants <28 weeks 1

If Positive Pressure Ventilation is Required

When the infant requires assisted ventilation despite CPAP:

• Use peak inspiratory pressure (PIP) of 20-25 cm H₂O initially 1
  • This delivers median tidal volumes of 9 (3-15.7) mL/kg in preterm infants
  • Higher pressures may sometimes be required, but titrate carefully
• Ventilation rate: 30-60 breaths per minute 1
• Inflation time: 0.5-1.0 seconds 1
  • Aligns with natural breathing patterns
  • Longer inflation times increase tidal volume delivery
• Apply PEEP of 5-6 cm H₂O 1

Critical Pitfall: The Sustained Aeration for Infant Lungs (SAIL) trial demonstrated significantly higher early mortality with sustained inflations (15 seconds at 25 cm H₂O) compared to standard ventilation in 426 infants 23-26 weeks gestation 1. This practice should be completely avoided.

Surfactant Administration Strategy

Selective vs. Prophylactic Approach

The paradigm has shifted: In the modern era with routine antenatal steroids (>90% exposure) and early CPAP stabilization, prophylactic surfactant is no longer superior and may be harmful 3.

Key Evidence from 2026 Cochrane Review:

• In infants stabilized on CPAP, prophylactic surfactant:
  • Makes little to no difference in chronic lung disease risk (RR 1.13,95% CI 1.00-1.28) 3
  • Probably slightly increases mortality 3
  • Does not reduce pneumothorax risk 3
• In contrast, selective surfactant administration after CPAP stabilization is the evidence-based approach 2, 3

When to Administer Surfactant Selectively

Indications for surfactant administration:

• Infant on CPAP/NIPPV with FiO₂ requirements ≥0.30-0.40 to maintain target saturations 2, 4
• Clinical and radiographic evidence of RDS
• Timing: Early rescue (<2 hours of age) decreases mortality, air leak, and chronic lung disease 2

Method of Administration: LISA/MIST Technique

Use Less Invasive Surfactant Administration (LISA) or Minimally Invasive Surfactant Therapy (MIST) via thin catheter rather than intubation-surfactant-extubation (InSurE) 5, 6, 7.

Evidence Supporting LISA in <28 Week Infants:

• Reduces need for mechanical ventilation by 28% (RR 0.72,95% CI 0.64-0.80) 6
• Decreases BPD incidence by 30% (RR 0.70,95% CI 0.66-0.75) 6
• Reduces early invasive ventilation burden: median 0 hours vs. 71 hours with intubation 5
• Lower incidence of hemodynamically significant PDA (35.0% vs. 69.1%) 5
• Lower nosocomial pneumonia rates (18.9% vs. 67.9%) 5
• No increase in mortality or severe IVH 5, 6

LISA Procedure:

• Maintain infant on CPAP/NIPPV throughout
• Insert thin catheter (5-6 Fr) into trachea under direct laryngoscopy
• Administer surfactant as bolus (typically 100-200 mg/kg poractant alfa or equivalent)
• Remove catheter immediately
• Continue non-invasive support

Alternative if LISA not feasible: Laryngeal mask airway (LMA) reduces subsequent intubation needs compared to endotracheal intubation, though evidence is less robust than for LISA 7.

Ongoing Ventilation Strategies

Non-Invasive Ventilation Preference

Maximize duration on non-invasive support (CPAP or NIPPV) to minimize invasive mechanical ventilation exposure 5, 4, 8:

• LISA-treated infants had median 51.5 days NIV vs. 37 days in intubated controls 5
• This trade-off (longer NIV, shorter IMV) improves outcomes

When Mechanical Ventilation is Unavoidable

Use volume-targeted ventilation (VTV) over pressure-limited ventilation 8:

• Reduces combined risk of BPD or death
• Improves multiple secondary outcomes without adverse events
• Set target tidal volume 4-6 mL/kg

Conventional vs. High-Frequency Oscillatory Ventilation (HFOV):

• No significant differences in meaningful outcomes between modes 8
• Choose based on institutional expertise and individual patient response

PEEP Management:

• No evidence-based guidelines for optimal PEEP settings 8
• Forced oscillation technique may help identify optimal PEEP for lung recruitment 8
• Typical starting PEEP: 5-6 cm H₂O, titrate based on oxygenation and lung mechanics

Ventilator Weaning and Extubation

• Target early extubation to non-invasive support whenever feasible
• Use caffeine therapy routinely to facilitate extubation 4
• Minimize total duration of mechanical ventilation through judicious use of postnatal corticosteroids when indicated 4

Adjunctive Therapies

Caffeine

• Initiate early (within first days of life) 4
• Facilitates extubation and reduces BPD risk
• Standard loading dose: 20 mg/kg caffeine citrate, maintenance 5-10 mg/kg/day

Oxygen Management

• Judicious oxygen use targeting SpO₂ 90-95% (adjust based on gestational age and postnatal age) 4
• Avoid both hypoxemia and hyperoxemia

Cardiovascular Support

• Appropriate hemodynamic management is crucial 4
• Monitor for and treat hemodynamically significant PDA, particularly as LISA reduces PDA incidence 5

Antibiotic Stewardship

• Judicious use of antibiotics—avoid unnecessary exposure 4
• Obtain cultures before initiating therapy
• Discontinue promptly if cultures negative and clinical improvement

Quality Improvement Considerations

Structured implementation of LISA protocols improves outcomes 5:

• Requires staff training and competency development
• Establish clear FiO₂ thresholds for intervention
• Monitor process measures (LISA success rate, time to surfactant)
• Track outcome measures (BPD rates, ventilation duration, mortality)

Critical Pitfalls to Avoid

1. Never use sustained inflations >5 seconds in infants <28 weeks—increases mortality 1
2. Avoid routine prophylactic intubation and surfactant in the CPAP era—increases mortality without benefit 3
3. Don't delay surfactant beyond 2 hours if FiO₂ criteria met—early rescue superior to late rescue 2
4. Avoid pressure-limited ventilation when volume-targeted ventilation available 8
5. Don't prolong mechanical ventilation unnecessarily—increases BPD risk 5, 4

Algorithm Summary

Birth → Immediate CPAP 5-6 cm H₂O → Monitor FiO₂ requirements:

• FiO₂ <0.30: Continue CPAP, start caffeine
• FiO₂ 0.30-0.40: Prepare for LISA, optimize CPAP settings first
• FiO₂ >0.40 persistently: Administer surfactant via LISA technique
• Post-surfactant: Continue non-invasive support, avoid intubation unless absolutely necessary
• If mechanical ventilation required: Use volume-targeted mode, target early extubation

This evidence-based approach, grounded in the most recent 2025 AHA/AAP guidelines 1 and 2026 Cochrane systematic review 3, prioritizes minimizing invasive ventilation exposure while ensuring timely surfactant delivery to reduce mortality and BPD in this extremely vulnerable population.